• Clinical Trials - Multiple Sclerosis (MS)

    Study Objective Contact
    A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (dimethyl fumarate) when Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) [LCID Study Number: 2014-002] This study is being done to gain a better understanding of the benefits and risks of long term treatment with Tecfidera (dimethyl fumarate) in patients with Multiple Sclerosis (MS). The main purpose of this observational study is to collect information on any side effects that may occur in patients taking Tecfidera. Principal Investigator(s):
    Claudia J. Chaves, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Rik Ganguly.
    A Multicenter, Observational, Open-Label, Single- Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients [LCID Study Number: 2012-001] Purpose: An observational study to determine which questionnaires and tests predict disease-free states for patients who are using Tysabri to treat early stages of Multiple Sclerosis. For more information on this study, please visit: http://www.lahey.org/Departments_and_Locations/Departments/Neurology/Research/Multiple_Sclerosis_Trials.aspx Principal Investigator(s):
    Claudia J. Chaves, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Nick Ventura,
    Rik Ganguly.
    A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients with Secondary Progressive Multiple Sclerosis [LCID Study Number: 2013-033] The purpose of this study is to test the effectiveness, safety and side effects of BAF312 (Siponimod) for patients with Secondary Progressive Multiple Sclerosis (SPMS). Principal Investigator(s):
    Ann Camac, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Nick Ventura,
    Rik Ganguly,
    Sharmeen Alam, MHA.
    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis, with optional open-label Extension [LCID Study Number: 2011-036] Purpose: To determine whether or not Tysabri is effective in reducing disability progression for Secondary Progressive Multiple Sclerosis (SPMS) patients as compared to Placebo. For more information on this study, please visit: http://www.lahey.org/Departments_and_Locations/Departments/Neurology/Research/Multiple_Sclerosis_Trials.aspx Principal Investigator(s):
    Ann Camac, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Rik Ganguly.
    An Open-Label, Two-Arm, Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning from Current Interferon Beta Therapies to BIIB017 [LCID Study Number: 2013-073] The purpose of this study is to test the effectiveness, safety and side effects of an experimental medication called BIIB017 that is being developed for patients with Multiple Sclerosis (MS). The purpose of the study is to find out if patients with relapsing MS (RMS) experience new and/or increased flu-like symptoms after switching from standard therapies (Avonex®, Betaseron®, Rebif®) to the investigational medication, BIIB017 Principal Investigator(s):
    Ann Camac, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Rik Ganguly.
    Mechanistic Studies of Phase III Trial with BAF 312 in Secondary Progressive Multiple Sclerosis (Protocol # AMS04) [LCID Study Number: 2015-001] The primary goal of this study is to evaluate the effects of BAF312 (siponimod) on select immune and neuronal (nerve) cells by examining laboratory specimens (blood and/or spinal fluid) at multiple time points, prior to, and following the initiation of BAF312 or placebo treatment, in patients with Secondary Progressive Multiple Sclerosis (SPMS) who are enrolled in a clinical trial (NCT01665144) to evaluate the effectiveness and safety of BAF312. ENROLLMENT BY INVITATION ONLY. Principal Investigator(s):
    Ann Camac, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Rik Ganguly,
    Sharmeen Alam, MHA.